- Pharmaceutical company AstraZeneca and Merck said their drug to treat prostate cancer had received marketing authorisation in the European Union.

The approval was based on a subgroup analysis of patients with breast cancer susceptibility gene 1/2 from a PROfound phase-three trial.

'This recommendation for Lynparza brings us closer to making the only PARP inhibitor to improve overall survival in this setting available to men in the EU,' AstraZeneca said.

AstraZeneca and Merck, known as MSD outside the US and Canada, said they were exploring additional trials to test test Lynparza as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer.

Data are anticipated in the second half of 2021, the companies said.

In a seperate statement released on 19 September, AstraZeneca also said a study showed that Tagrisso had demonstrated a 'clinically meaningful improvement' in patients with non-small cell lung cancer.

Tagrisso showed an 82% reduction in the risk of central nervours system recurrence or death, the company said.

Story provided by